Back to search

Article

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical Trial

2023-02-07

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> 500 mg intravenous (IV) sotrovimab has been shown to be well tolerated and efficacious against pre-Omicron strains in treating patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk for disease progression. <h4>Methods</h4> This was an open-label, single-arm substudy of phase 3 COMET-TAIL ( NCT04913675 ) assessing the safety and tolerability of a 2000...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
69083036-641c-5e3a-82c2-bb79a3a9d0af
DOI
10.1101/2023.02.02.23285352
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical TrialDOI 10.1101/2023.02.02.23285352
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical TrialSemantic proximity
Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in EnglandSemantic proximity
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in ScotlandSemantic proximity
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature reviewSemantic proximity
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron PhaseSemantic proximity
Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19Semantic proximity
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron PhaseSemantic proximity
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trialSemantic proximity
Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving SotrovimabSemantic proximity
Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.Semantic proximity
Select a neighboring publication to make it the new centre.